Trial Profile
Perioperative Therapy for Resectable Pancreatic Adenocarcinoma and Borderline Resectable Pancreatic Adenocarcinoma With Molecular Correlates
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 29 Mar 2023 Planned End Date changed from 1 Mar 2023 to 1 May 2024.
- 29 Mar 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Aug 2023.
- 08 Mar 2022 Planned End Date changed from 1 May 2022 to 1 Mar 2023.